Holen Sie sich die Stockscreener-App
117.14
0.13%
0.15
Handel nachbörslich:
117.25
0.11
+0.09%
Schlusskurs vom Vortag:
$116.99
Offen:
$116.99
24-Stunden-Volumen:
463.77K
Relative Volume:
0.76
Marktkapitalisierung:
$5.85B
Einnahmen:
$338.46M
Nettoeinkommen (Verlust:
$-310.96M
KGV:
-17.94
EPS:
-6.53
Netto-Cashflow:
$-132.82M
1W Leistung:
+7.71%
1M Leistung:
+6.80%
6M Leistung:
-14.96%
1J Leistung:
+33.25%
1-Tages-Spanne:
$114.49
$117.29
1-Wochen-Bereich:
$108.04
$117.29
52-Wochen-Spanne:
$75.56
$139.13
Axsome Therapeutics Inc Stock (AXSM) Company Profile
Firmenname
Axsome Therapeutics Inc
Sektor
Branche
Telefon
(212) 332-3241
Adresse
ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK
Vergleichen Sie AXSM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AXSM
Axsome Therapeutics Inc
|
117.14 | 5.55B | 338.46M | -310.96M | -132.82M | -6.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.46 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
598.16 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
467.55 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
663.73 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.97 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-03 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-06-03 | Eingeleitet | Oppenheimer | Outperform |
| 2025-04-07 | Eingeleitet | Jefferies | Buy |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2024-12-31 | Bestätigt | Mizuho | Outperform |
| 2024-09-03 | Eingeleitet | Wells Fargo | Overweight |
| 2024-08-06 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-07-22 | Eingeleitet | Needham | Buy |
| 2024-04-29 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-03-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-02-06 | Eingeleitet | UBS | Buy |
| 2024-01-25 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-12-13 | Eingeleitet | Citigroup | Buy |
| 2023-08-08 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2023-01-05 | Eingeleitet | Piper Sandler | Neutral |
| 2022-11-01 | Eingeleitet | Loop Capital | Buy |
| 2022-09-07 | Fortgesetzt | Mizuho | Buy |
| 2021-08-10 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-06-10 | Eingeleitet | Berenberg | Buy |
| 2021-01-08 | Eingeleitet | Jefferies | Buy |
| 2020-12-16 | Eingeleitet | Mizuho | Buy |
| 2020-09-29 | Eingeleitet | BofA Securities | Underperform |
| 2020-09-10 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-04-28 | Bestätigt | H.C. Wainwright | Buy |
| 2020-04-14 | Eingeleitet | Cowen | Outperform |
| 2019-12-30 | Bestätigt | H.C. Wainwright | Buy |
| 2019-12-17 | Bestätigt | H.C. Wainwright | Buy |
| 2019-12-16 | Bestätigt | Guggenheim | Buy |
| 2019-10-16 | Eingeleitet | Guggenheim | Buy |
| 2019-09-18 | Eingeleitet | William Blair | Outperform |
| 2019-05-28 | Eingeleitet | SunTrust | Buy |
| 2019-05-23 | Bestätigt | H.C. Wainwright | Buy |
| 2019-04-08 | Eingeleitet | SVB Leerink | Outperform |
| 2019-03-15 | Bestätigt | H.C. Wainwright | Buy |
| 2016-10-03 | Fortgesetzt | Brean Capital | Buy |
| 2015-12-15 | Eingeleitet | Cantor Fitzgerald | Buy |
| 2015-12-14 | Eingeleitet | Ladenburg Thalmann | Buy |
Alle ansehen
Axsome Therapeutics Inc Aktie (AXSM) Neueste Nachrichten
Axsome stock rating reiterated at Outperform by RBC, citing FDA flexibility - Investing.com
Vanguard Group Inc. Sells 25,537 Shares of Axsome Therapeutics, Inc. $AXSM - MarketBeat
Wyckoff Accumulation Phase Possible in Axsome Therapeutics Inc.2025 Big Picture & Growth Focused Investment Plans - classian.co.kr
Fox Run Management L.L.C. Acquires 7,465 Shares of Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome Therapeutics, Inc. $AXSM Shares Purchased by Invesco Ltd. - MarketBeat
Deutsche Bank AG Cuts Holdings in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Nuveen LLC Invests $48.19 Million in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Quant Tools Rank Axsome Therapeutics Inc. as High Risk High RewardJuly 2025 Technicals & Weekly High Conviction Trade Ideas - thegnnews.com
Versor Investments LP Acquires Shares of 19,615 Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome Therapeutics, Inc. $AXSM Shares Acquired by Charles Schwab Investment Management Inc. - MarketBeat
Axsome Therapeutics Inc. Approaches Support With Recovery in SightJuly 2025 Sector Moves & Stock Market Timing Techniques - sundaytimes.kr
What's Going On With Tonix Pharma Stock Monday?Tonix Pharmaceuticals (NASDAQ:TNXP) - Benzinga
Virtu Financial LLC Takes $931,000 Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Informed Momentum Co LLC Purchases Shares of 42,222 Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Can Axsome Therapeutics Inc. continue delivering strong returnsWeekly Profit Analysis & Fast Exit Strategy with Risk Control - thegnnews.com
Connor Clark & Lunn Investment Management Ltd. Has $20.52 Million Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
XTX Topco Ltd Sells 9,794 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Cantor Fitzgerald Has Positive View of AXSM FY2026 Earnings - MarketBeat
Equities Analysts Set Expectations for AXSM Q3 Earnings - MarketBeat
HC Wainwright Issues Negative Estimate for AXSM Earnings - MarketBeat
Cantor Fitzgerald Issues Negative Forecast for AXSM Earnings - MarketBeat
Leerink Partnrs Issues Positive Forecast for AXSM Earnings - MarketBeat
Equities Analysts Issue Forecasts for AXSM Q3 Earnings - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q2 2025 Earnings Call Transcript - MSN
Royal Bank Of Canada Raises Axsome Therapeutics (NASDAQ:AXSM) Price Target to $189.00 - MarketBeat
TD Asset Management Inc Takes Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics' (AXSM) Buy Rating Reiterated at Needham & Company LLC - MarketBeat
Axsome outlines late-stage pipeline advancements and targets cash flow positivity amid 72% revenue growth - MSN
Axsome Therapeutics (NASDAQ:AXSM) Announces Quarterly Earnings Results, Beats Estimates By $0.08 EPS - MarketBeat
Federated Hermes Inc. Acquires Shares of 25,990 Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics Jumps 5% as Q2 Revenue Surpasses Projections - MSN
Finanzdaten der Axsome Therapeutics Inc-Aktie (AXSM)
Umsatz
Nettogewinn
Free Cashflow
ENV
Axsome Therapeutics Inc-Aktie (AXSM) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Murdock Hunter R. | General Counsel |
Jun 23 '25 |
Option Exercise |
29.91 |
6,014 |
179,879 |
6,014 |
| Murdock Hunter R. | General Counsel |
Jun 20 '25 |
Sale |
102.47 |
7,500 |
768,525 |
0 |
| Murdock Hunter R. | General Counsel |
Jun 23 '25 |
Sale |
100.12 |
6,014 |
602,122 |
0 |
1.55%
0.38%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):